The International Myeloma Foundation Says Newly Diagnosed Patients Could Benefit from FDA “Priority Review’’ of VELCADE(R) for Front-Line Use

NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) – supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians – today said the FDA decision granting “priority review” for VELCADE® in newly diagnosed myeloma recognizes the benefits of powerful new therapies and the need to get them to more patients sooner.